Rising concern over a Bundibugyo ebolavirus outbreak in eastern Democratic Republic of Congo (DRC) has intensified interest in broad-spectrum antiviral candidates that could target multiple filoviruses.
Ebola virus disease is a severe haemorrhagic illness spread through bodily fluids, with recent outbreaks associated with mortality rates of around 50% despite supportive care improvements.
NanoViricides, Inc. has highlighted NV-387, an investigational oral antiviral designed to mimic sulfated proteoglycans, which many filoviruses use to attach to human cells. The company believes this mechanism could make the treatment active against the Bundibugyo strain currently affecting DRC and Uganda, while potentially reducing the likelihood of viral escape through mutation.
No approved treatments or vaccines for Bundibugyo Ebola strain
The outbreak was declared on the 15th of May 2026, although the suspected index case may have occurred several weeks earlier in remote regions with limited reporting capacity.
At least 336 suspected cases and 88 deaths have already been reported, and there are no approved treatments or vaccines specifically targeting Bundibugyo virus. This is because existing authorised therapies focus largely on the Zaire strain of Ebola.
Investigational oral antiviral targets shared filovirus attachment pathway
NV-387 is being developed as a room-temperature-stable oral therapy, including gummy formulations intended to simplify administration in children, older adults, and patients with swallowing difficulties or sore throat symptoms. NanoViricides argues that a shelf-stable antiviral could help address logistical challenges associated with outbreak response in resource-limited settings.
The drug is based on the observation that filoviruses rely on sulphated proteoglycans for initial cell attachment, regardless of genetic variation. According to the company, this shared dependency may reduce the potential for resistance compared with strain-specific vaccines or antibody therapies.
However, NV-387 remains investigational, and its effectiveness against Bundibugyo virus or other filoviruses has not yet been established in clinical settings. The company also noted that there is currently no indication of a global Ebola pandemic threat, although increasing international travel could heighten the risk of wider spread if outbreaks are not rapidly contained.
Reference
Access Newswire. Ebola global health emergency needs a broad-spectrum drug – NV-387 is a strong potential candidate, says NanoViricides. 2026. Available at: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/ebola-global-health-emergency-needs-a-broad-spectrum-drug-nv-387-is-a-1167692. Last accessed: 18 May 2026.
Featured image: jaddingt on Adobe Stock
